Drug Patents Expiring in 2039
1. List of Airduo Digihaler drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US11000653
(Pediatric) | TEVA PHARM | Inhaler |
Jun, 2039
(16 years from now) | |
| US11344685 | TEVA PHARM | Drug delivery device with electronics |
Sep, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jul 9, 2024 |
| Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
2. List of Anjeso drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10881663 | BAUDAX | Method of treating pain in elderly patients with mild renal impairment |
Mar, 2039
(16 years from now) | |
| US11458145 | BAUDAX | Methods of administering intravenous meloxicam in a bolus dose |
Mar, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Feb 20, 2023 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 20 February, 2020
Treatment: Management of moderate-to-severe pain by intravenous injection in patients with mild renal impairment; Management of moderate-to-severe pain by injection
Dosage: SOLUTION;INTRAVENOUS
3. List of Annovera drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10765628 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(16 years from now) | |
| US10632066 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(16 years from now) | |
| US10780047 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(16 years from now) | |
| US10918649 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(16 years from now) | |
| US10925882 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(16 years from now) | |
| US10940157 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(16 years from now) | |
| US11529308 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 10, 2023 |
Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient
NCE-1 date: August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: Method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles; Method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception
Dosage: RING;VAGINAL
4. List of Aristada drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11273158 | ALKERMES INC | Aripiprazole dosing strategy |
Apr, 2039
(16 years from now) | |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
5. List of Aristada Initio Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11273158 | ALKERMES INC | Aripiprazole dosing strategy |
Apr, 2039
(16 years from now) | |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
Market Authorisation Date: 29 June, 2018
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
6. List of Armonair Digihaler drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US11000653
(Pediatric) | TEVA PHARM | Inhaler |
Jun, 2039
(16 years from now) | |
| US11344685 | TEVA PHARM | Drug delivery device with electronics |
Sep, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jul 9, 2024 |
| New Strength (NS) | Jul 9, 2024 |
| Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
7. List of Baqsimi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10765602 | ELI LILLY AND CO | Medication delivery systems and methods |
Sep, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Jul 24, 2022 |
Drugs and Companies using GLUCAGON ingredient
Market Authorisation Date: 24 July, 2019
Treatment: NA
Dosage: POWDER;NASAL
8. List of Bylvay drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10975046 | ALBIREO | Crystal modifications of odevixibat |
Jun, 2039
(16 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11365182 | ALBIREO | Crystal modifications of odevixibat |
Jun, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 20, 2026 |
| Orphan Drug Exclusivity (ODE) | Jul 20, 2028 |
Drugs and Companies using ODEVIXIBAT ingredient
NCE-1 date: July, 2025
Market Authorisation Date: 20 July, 2021
Treatment: Method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic)
Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL
9. List of Caplyta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10695345 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(16 years from now) | |
| US11052084 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 20, 2024 |
| New Indication (I) | Dec 17, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: December, 2023
Market Authorisation Date: 20 December, 2019
Treatment: Treatment of schizophrenia; Treatment of bipolar depression mediated by the 5-ht2a receptor, serotonin transporter, and/or dopamine d1/d2 signaling pathways; Treatment of schizophrenia mediated by the 5-ht2a receptor, serotonin transporter, and/or dopamine d1/d2 signaling pathways
Dosage: CAPSULE;ORAL
10. List of Cuvrior drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10988436 | ORPHALAN | Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use |
May, 2039
(16 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11072577 | ORPHALAN | Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use |
May, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Apr 28, 2025 |
Drugs and Companies using TRIENTINE TETRAHYDROCHLORIDE ingredient
Market Authorisation Date: 28 April, 2022
Treatment: A method for the treatment of adult patients with stable wilson’s disease who are de-coppered and tolerant to penicillamine
Dosage: TABLET;ORAL
11. List of Dexycu Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11097061 | EYEPOINT PHARMS | Systems, kits and methods for loading and delivering a small volume dose from a syringe |
Jun, 2039
(16 years from now) | |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 09 February, 2018
Treatment: A method of loading medication into a syringe and delivering the medication to a treatment site
Dosage: SUSPENSION;INTRAOCULAR
12. List of Dhivy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033521 | AVION PHARMS | Levodopa fractionated dose composition and use |
Mar, 2039
(16 years from now) | |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Market Authorisation Date: 12 November, 2021
Treatment: Treatment of parkinson's disease; Method of treating parkinson's disease by orally administering segments of a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg, each segment having carbidopa—6.25 mg/levodopa—25 mg; Method of treating parkinson's disease by orally administering a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg
Dosage: TABLET;ORAL
13. List of Elcys drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10653719 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10918662 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10933089 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10912795 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10905714 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10478453 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10583155 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10905713 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US11510941 | EXELA PHARMA | NA |
Jan, 2039
(15 years from now) | |
| US11510942 | EXELA PHARMA | NA |
Jan, 2039
(15 years from now) | |
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 April, 2019
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition
Dosage: SOLUTION;INTRAVENOUS
14. List of Elucirem drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10973934 | GUERBET | Gadolinium bearing PCTA-based contrast agents |
Aug, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 21, 2027 |
Drugs and Companies using GADOPICLENOL ingredient
NCE-1 date: September, 2026
Market Authorisation Date: 21 September, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
15. List of Epidiolex drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11207292 | GW RES LTD | Cannabidiol preparations and its uses |
Apr, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 28, 2023 |
| Orphan Drug Exclusivity (ODE) | Jul 31, 2027 |
| New Patient Population (NPP) | Jul 31, 2023 |
Drugs and Companies using CANNABIDIOL ingredient
NCE-1 date: September, 2022
Market Authorisation Date: 28 September, 2018
Treatment: Use for the treatment of seizures associated with dravet syndrome; Use for the treatment of seizures associated with tuberous sclerosis complex; Use for the treatment of seizures associated with lennox-gastaut syndrome
Dosage: SOLUTION;ORAL
16. List of Fotivda drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11504365 | AVEO PHARMS | NA |
Nov, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 10, 2026 |
Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient
NCE-1 date: March, 2025
Market Authorisation Date: 10 March, 2021
Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally for 21 days followed by no drug for 7 days
Dosage: CAPSULE;ORAL
17. List of Galafold drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11357784 | AMICUS THERAP US | Use of migalastat for treating Fabry disease in pregnant patients |
Feb, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity (ODE) | Aug 10, 2025 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients
Dosage: CAPSULE;ORAL
18. List of Gavreto drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11273160 | GENENTECH INC | RET inhibitor for use in treating cancer having a RET alteration |
Apr, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 4, 2025 |
| Orphan Drug Exclusivity (ODE) | Sep 4, 2027 |
Drugs and Companies using PRALSETINIB ingredient
NCE-1 date: September, 2024
Market Authorisation Date: 04 September, 2020
Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test
Dosage: CAPSULE;ORAL
19. List of Igalmi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10792246 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(16 years from now) | |
| US11517524 | BIOXCEL | NA |
Jun, 2039
(16 years from now) | |
| US11478422 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(16 years from now) | |
| US11497711 | BIOXCEL | NA |
Jun, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Apr 5, 2025 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2022
Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual administration
Dosage: FILM;BUCCAL, SUBLINGUAL
20. List of Ingrezza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11026931 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 11, 2022 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: April, 2021
Market Authorisation Date: 11 April, 2017
Treatment: Treatment of tardive dyskinesia
Dosage: CAPSULE;ORAL
21. List of Inrebic drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11400092 | IMPACT | Methods of treating myeloproliferative disorders |
Sep, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 16, 2026 |
| New Chemical Entity Exclusivity (NCE) | Aug 16, 2024 |
Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient
NCE-1 date: August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring thiamine levels and administering thiamine or a thiamine equivalent
Dosage: CAPSULE;ORAL
22. List of Katerzia drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10799453 | AZURITY | Amlodipine formulations |
Apr, 2039
(16 years from now) | |
Drugs and Companies using AMLODIPINE BENZOATE ingredient
Market Authorisation Date: 08 July, 2019
Treatment: NA
Dosage: SUSPENSION;ORAL
23. List of Konvomep drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10751333 | AZURITY | Compositions and kits for omeprazole suspension |
Jul, 2039
(16 years from now) | |
| US11103492 | AZURITY | Compositions and kits for omeprazole suspension |
Jul, 2039
(16 years from now) | |
Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient
Market Authorisation Date: 30 August, 2022
Treatment: NA
Dosage: FOR SUSPENSION;ORAL
24. List of Lyvispah drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10792262 | AMNEAL | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
Jul, 2039
(16 years from now) | |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 22 November, 2021
Treatment: Method for treating spasticity
Dosage: GRANULES;ORAL
25. List of Mounjaro drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: May, 2026
Market Authorisation Date: 13 May, 2022
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
26. List of Norepinephrine Bitartrate In 0.9% Sodium Chloride drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10888534 | INFORLIFE | Storage stable ready-to-use norepinephrine aqueous solutions in flexible plastic bags |
Apr, 2039
(16 years from now) | |
Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient
Market Authorisation Date: 15 September, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
27. List of Nouress drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10653719 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10912795 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10918662 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10583155 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10478453 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10933089 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10905713 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10905714 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(15 years from now) | |
| US10493051 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(16 years from now) | |
| US11045438 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(16 years from now) | |
| US10543186 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(16 years from now) | |
| US10702490 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(16 years from now) | |
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 December, 2019
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition; Method of intravenously administering a diluted cysteine hydrochloride solution to a neonate in need thereof
Dosage: SOLUTION;INTRAVENOUS
28. List of Nurtec Odt drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11083724 | BIOHAVEN IRELAND | Rimegepant for CGRP related disorders |
Mar, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 27, 2025 |
| New Indication (I) | May 27, 2024 |
Drugs and Companies using RIMEGEPANT SULFATE ingredient
NCE-1 date: February, 2024
Market Authorisation Date: 27 February, 2020
Treatment: Acute treatment of migraine with or without aura in adults; Preventive treatment of episodic migraine in adults
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
29. List of Orladeyo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10662160 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(16 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11117867 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 3, 2027 |
| New Chemical Entity Exclusivity (NCE) | Dec 3, 2025 |
Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient
NCE-1 date: December, 2024
Market Authorisation Date: 03 December, 2020
Treatment: Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older
Dosage: CAPSULE;ORAL
30. List of Ozobax drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610502 | METACEL PHARMS LLC | Oral baclofen solutions |
Aug, 2039
(16 years from now) | |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 18 September, 2019
Treatment: Treatment of spasticity
Dosage: SOLUTION;ORAL
31. List of Pedmark drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11510984 | FENNEC PHARMS INC | Anhydrous sodium thiosulfate and formulations thereof |
Jul, 2039
(16 years from now) | |
| US11291728 | FENNEC PHARMS INC | Anhydrous sodium thiosulfate and formulations thereof |
Jul, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Sep 20, 2025 |
Drugs and Companies using SODIUM THIOSULFATE ingredient
Market Authorisation Date: 20 September, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
32. List of Pemazyre drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11466004 | INCYTE CORP | Solid forms of an FGFR inhibitor and processes for preparing the same |
May, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 17, 2025 |
| Orphan Drug Exclusivity (ODE) | Apr 17, 2027 |
| New Indication (I) | Aug 26, 2025 |
Drugs and Companies using PEMIGATINIB ingredient
NCE-1 date: April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering once daily a tablet containing about 0.5 mg to about 10 mg of pemigatinib; Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib qd for 14 days then not administering pemigatinib for 7 days in a 21-day cycle; Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib in a daily dose of about 5 mg to about 20 mg
Dosage: TABLET;ORAL
33. List of Potassium Phosphates drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10632150 | CMP DEV LLC | Potassium phosphates composition for injection |
Apr, 2039
(16 years from now) | |
Drugs and Companies using POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC ingredient
Market Authorisation Date: 19 September, 2019
Treatment: Potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older
Dosage: SOLUTION;INTRAVENOUS
34. List of Proair Digihaler drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11344685 | TEVA BRANDED PHARM | Drug delivery device with electronics |
Sep, 2039
(16 years from now) | |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 31 March, 2015
Treatment: NA
Dosage: POWDER, METERED;INHALATION
35. List of Qvar Redihaler drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10792447 | NORTON WATERFORD | Breath actuated inhaler |
Jan, 2039
(16 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
36. List of Radicava Ors drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11241416 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(16 years from now) | |
| US10987341 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(16 years from now) | |
| US11478450 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | May 12, 2025 |
Drugs and Companies using EDARAVONE ingredient
Market Authorisation Date: 12 May, 2022
Treatment: Treatment of amyotrophic lateral sclerosis
Dosage: SUSPENSION;ORAL
37. List of Rezlidhia drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10532047 | RIGEL PHARMS INC | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(16 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11376246 | RIGEL PHARMS INC | Inhibiting mutant IDH-1 |
May, 2039
(16 years from now) | |
| US11497743 | RIGEL PHARMS INC | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
May, 2039
(16 years from now) | |
| US10959994 | RIGEL PHARMS INC | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(16 years from now) | |
| US11013734 | RIGEL PHARMS INC | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
May, 2039
(16 years from now) | |
| US11013733 | RIGEL PHARMS INC | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
May, 2039
(16 years from now) | |
Drugs and Companies using OLUTASIDENIB ingredient
Market Authorisation Date: 01 December, 2022
Treatment: A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation; A method of treating a cancer characterized by an idh1 mutation where the cancer is acute myeloid leukemia (aml)
Dosage: CAPSULE;ORAL
38. List of Sotalol Hydrochloride drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10799138 | ALTATHERA PHARMS LLC | Method of administering sotalol IV/switch |
Apr, 2039
(16 years from now) | |
Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient
Market Authorisation Date: 02 July, 2009
Treatment: Use for loading dose in patients with symptomatic afib/afl who are currently in sinus rhythm or for the treatment of life-threatening ventricular tachycardia
Dosage: SOLUTION;INTRAVENOUS
39. List of Sympazan drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11541002 | OTTER PHARMS | NA |
Sep, 2039
(16 years from now) | |
Drugs and Companies using CLOBAZAM ingredient
Market Authorisation Date: 01 November, 2018
Treatment: Method of treating seizures
Dosage: FILM;ORAL
40. List of Testosterone Cypionate drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11311554 | SLAYBACK PHARMA LLC | Pharmaceutical compositions of testosterone |
Mar, 2039
(16 years from now) | |
Drugs and Companies using TESTOSTERONE CYPIONATE ingredient
Market Authorisation Date: 02 June, 2022
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR
41. List of Tibsovo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10980788 | SERVIER | Therapy for treating malignancies |
Jun, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 20, 2023 |
| Orphan Drug Exclusivity (ODE) | Aug 25, 2028 |
| New Indication (I) | May 25, 2025 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: July, 2022
Market Authorisation Date: 20 July, 2018
Treatment: A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; Treating newly diagnosed acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; Treating relapsed/refractory acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal
Dosage: TABLET;ORAL
42. List of Trudhesa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11185497 | IMPEL NEUROPHARMA | Intranasal delivery of dihydroergotamine by precision olfactory device |
Jan, 2039
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Sep 2, 2024 |
Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient
Market Authorisation Date: 02 September, 2021
Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura
Dosage: SPRAY, METERED;NASAL
43. List of Upneeq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11311515 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(16 years from now) | |
| US11324722 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(16 years from now) | |
| US11103482 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(16 years from now) | |
| US10940138 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(16 years from now) | |
| US10799481 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(16 years from now) | |
| US10814001 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(16 years from now) | |
| US10898573 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(16 years from now) | |
| US11541036 | RVL PHARMS | NA |
Dec, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Jul 8, 2023 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 July, 2020
Treatment: Method of treating blepharoptosis
Dosage: SOLUTION/DROPS;OPHTHALMIC
44. List of Vabomere drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11376237 | REMPEX | Methods of treating bacterial infections |
Apr, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 29, 2022 |
| Generating Antibiotic Incentives Now (GAIN) | Aug 29, 2027 |
Drugs and Companies using MEROPENEM; VABORBACTAM ingredient
NCE-1 date: August, 2026
Market Authorisation Date: 29 August, 2017
Treatment: Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli,klebsiella pneumonia,enterobacter cloacae species complex with meropenem & vaborbactam as specified
Dosage: POWDER;INTRAVENOUS
45. List of Vuity drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11285134 | ABBVIE INC | Presbyopia treatments |
Apr, 2039
(16 years from now) | |
| US10610518 | ABBVIE INC | Presbyopia treatments |
Apr, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Oct 28, 2024 |
Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 October, 2021
Treatment: Use of vuity for the treatment of presbyopia in adults
Dosage: SOLUTION;OPHTHALMIC
46. List of Xarelto drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10828310 | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jan, 2039
(16 years from now) | |
|
US10828310
(Pediatric) | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jul, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Aug 23, 2024 |
| M | Mar 10, 2023 |
| Pediatric Exclusivity (PED) | Apr 11, 2023 |
Drugs and Companies using RIVAROXABAN ingredient
Market Authorisation Date: 01 July, 2011
Treatment: Reduction of risk of cardiovascular death, myocardial infarction, and stroke in patients with cad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily; Reduction of risk of myocardial infarction and ischemic stroke in patients with pad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily
Dosage: TABLET;ORAL
47. List of Yupelri drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11484531 | MYLAN IRELAND LTD | NA |
Oct, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 9, 2023 |
Drugs and Companies using REVEFENACIN ingredient
NCE-1 date: November, 2022
Market Authorisation Date: 09 November, 2018
Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: SOLUTION;INHALATION
48. List of Zimhi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11027072 | ADAMIS PHARMS CORP | Emergency devices |
May, 2039
(16 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2021
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
availability in other generic markets.
Click on the highlighted region to filter.
List of large molecules
1. List of Eylea large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10973879 | REGENERON PHARMACEUTICALS, INC. | Use of a VEGF antagonist to treat angiogenic eye disorders |
May, 2039
(16 years from now) | |
| US11160918 | REGENERON PHARMACEUTICALS, INC. | Medical device packaging and related methods |
Jul, 2039
(16 years from now) |
Ingredients: AFLIBERCEPT
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic